American Journal of Surgical Pathology:
July 2011 - Volume 35 - Issue 7 - p 937–948
doi: 10.1097/PAS.0b013e31821c3dae
Original Articles
SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas
Magnusson, Kristina MSc*; de Wit, Meike MSc†; Brennan, Donal J. MD, PhD‡; Johnson, Louis B. MD, PhD§; McGee, Sharon F. PhD‡; Lundberg, Emma PhD∥; Naicker, Kirsha MSc‡; Klinger, Rut MSc‡; Kampf, Caroline PhD*; Asplund, Anna PhD*; Wester, Kenneth PhD*; Gry, Marcus PhD*,∥; Bjartell, Anders MD, PhD§,¶; Gallagher, William M. PhD‡; Rexhepaj, Elton PhD‡; Kilpinen, Sami PhD♯,**; Kallioniemi, Olli-Pekka MD, PhD♯; Belt, Eric MD†; Goos, Jeroen MSc†; Meijer, Gerrit MD, PhD†; Birgisson, Helgi MD, PhD††; Glimelius, Bengt MD, PhD‡‡,§§; Borrebaeck, Carl A.K. PhD∥∥; Navani, Sanjay MD¶¶; Uhlén, Mathias PhD∥; O'Connor, Darran P. PhD‡; Jirström, Karin MD, PhD♯♯; Pontén, Fredrik MD, PhD*

Abstract
The special AT-rich sequence-binding protein 2 (SATB2), a nuclear matrix-associated transcription factor and epigenetic regulator, was identified as a tissue type-specific protein when screening protein expression patterns in human normal and cancer tissues using an antibody-based proteomics approach. In this respect, the SATB2 protein shows a selective pattern of expression and, within cells of epithelial lineages, SATB2 expression is restricted to glandular cells lining the lower gastrointestinal tract. Zxcvbn,The expression of SATB2 protein is primarily preserved in cancer cells of colorectal origin, indicating that SATB2 could function as a clinically useful diagnostic marker to distinguish colorectal cancer (CRC) from other types of cancer. The aim of this study was to further explore and validate the specific expression pattern of SATB2 as a clinical biomarker and to compare SATB2 with the well-known cytokeratin 20 (CK20). Immunohistochemistry was used to analyze the extent of SATB2 expression in tissue microarrays with tumors from 9 independent cohorts of patients with primary and metastatic CRCs (n=1882). Our results show that SATB2 is a sensitive and highly specific marker for CRC with distinct positivity in 85% of all CRCs, and that SATB2 and/or CK20 was positive in 97% of CRCs. In conclusion, the specific expression of SATB2 in a large majority of CRCs suggests that SATB2 can be used as an important complementary tool for the differential diagnosis of carcinoma of unknown primary origin.
SATB2 与CK 20 合用可鉴别95%以上的结肠直肠癌
富含AT序列的特异性结合蛋白2(SATB2)是一种核基质相关转录因子和遗传调控子，它是在用基于抗体的蛋白组学方法筛选蛋白表达方式时发现的一种组织型特定的蛋白质。在这点上，蛋白显示出选择性的表达方式以及在上皮细胞内部表达，并且SATB2的表达仅限于下消化道的腺上皮。SATB2蛋白主要在结肠直肠来源的癌细胞中表达，表示SATB2可以作为鉴别结肠直肠癌(CRC)和其他类型癌症的一个临床有效的诊断标记。本研究的目的在于更进一步探索和验证SATB2作为临床生物标记物的特异性表达方式以及比较SATB2与众所周知的细胞角蛋白20(CK20)联合应用的鉴别效果。我们用免疫组织化学的方法分析了有原发性和转移性 CRCs (n=1882)中9例独立群组的组织微阵列的SATB2表达程度。本研究结果显示SATB2是CRC的敏感且高度特异的标记，SATB2在85%的CRCs中特异性阳性表达，在97% 的CRCs中SATB2 和/或 CK20为阳性。总之，SATB2在绝大多数 CRCs中特异性表达显示在鉴别诊断起源不明的癌症时 SATB2 可以作为一个重要的补充工具。